108139
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
右美托咪定联合艾司氯胺酮可降低神经外科儿科术后谵妄风险：一项随机对照试验
Authors Wen CY , Bao J, Zhou Y, Mu DL, Ding T
Received 1 July 2025
Accepted for publication 20 September 2025
Published 30 September 2025 Volume 2025:19 Pages 8865—8877
DOI https://doi.org/10.2147/DDDT.S550647
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 5
Editor who approved publication: Professor Anastasios Lymperopoulos
Chen-Yu Wen,1,* Ju Bao,1,* Yin Zhou,2 Dong-Liang Mu,1,3 Ting Ding1,3
1Department of Anesthesiology, Peking University First Hospital, Beijing, People’s Republic of China; 2Department of Anesthesiology, Peking University School and Hospital of Stomatology, Beijing, People’s Republic of China; 3Outcomes Research Consortium, Cleveland, OH, USA
*These authors contributed equally to this work
Correspondence: Dong-Liang Mu; Ting Ding, Department of Anesthesiology, Peking University First Hospital, Beijing, 100034, People’s Republic of China, Tel +86 10 83572784, Fax +86 10 66551057, Email mudongliang@bjmu.edu.cn; dingting01@bjmu.edu.cn
Purpose: Present study was designed to investigate whether combined esketamine and dexmedetomidine could decrease the risk of postoperative delirium in neurosurgical pediatric.
Patients and Methods: In this prospective randomized controlled study, pediatrics (aged 2– 16 years) who were scheduled for selective neurosurgery were enrolled. Patients were randomized to receive combined esketamine (0.5 mg/kg) and dexmedetomidine (0.5 μg/kg) or normal saline as placebo at anesthesia induction. Primary outcome was the incidence of delirium within postoperative the first five days which was assessed twice daily using the Cornell Assessment of Pediatric Delirium (CAPD). CAPD≥ 10 at any assessment point was considered as delirium. Secondary outcomes included the incidence of emergence delirium, non-delirium complications within postoperative 30 days, postoperative length of in-hospital stay, and medical cost during hospitalization. The change of systematic inflammation was reflected by Neutrophil-to-Lymphocyte Ratio.
Results: From July 2021 to March 2023, 270 patients were screened, and 190 patients were randomized. Median age of enrolled patients was similar between two groups (63.0 [43.3, 111.3] vs 70.0 [46.3, 114.8] months, P = 0.883). Patients in esketamine-dex group suffered lower incidence of postoperative delirium than control group (intention-to-treat analysis: 22.8% [21/92] vs 38.0% [35/92], RR = 0.600, 95% CI 0.380– 0.948, P = 0.025; per-protocol analysis: 22.0% [20/91] vs 38.2% [34/89], RR = 0.575, 95% CI 0.360– 0.919, P = 0.018). The incidence of emergence delirium was lower in esketamine-dex group than control group (20.7% [19/92] vs 50.0% [46/92], RR = 0.413, 95% CI 0.263– 0.648, P < 0.001). Patients in esketamine-dex group had lower medical cost (P < 0.001), and there was no statistical significance in the incidence of non-delirium complications within postoperative 30 days and postoperative length of in-hospital stay. The neutrophil-to-lymphocyte ratios at postoperative first and third day were comparable between two groups. Safety outcomes such as bradycardia and hypotension were comparable between groups.
Conclusion: Combined esketamine and dexmedetomidine could decrease the risk postoperative delirium and emergence delirium in pediatrics after neurosurgery.
Keywords: pediatric, neurosurgery, esketamine, dexmedetomidine, delirium
1Department of Anesthesiology, Peking University First Hospital, Beijing, People’s Republic of China; 2Department of Anesthesiology, Peking University School and Hospital of Stomatology, Beijing, People’s Republic of China; 3Outcomes Research Consortium, Cleveland, OH, USA
*These authors contributed equally to this work
Correspondence: Dong-Liang Mu; Ting Ding, Department of Anesthesiology, Peking University First Hospital, Beijing, 100034, People’s Republic of China, Tel +86 10 83572784, Fax +86 10 66551057, Email mudongliang@bjmu.edu.cn; dingting01@bjmu.edu.cn
Purpose: Present study was designed to investigate whether combined esketamine and dexmedetomidine could decrease the risk of postoperative delirium in neurosurgical pediatric.
Patients and Methods: In this prospective randomized controlled study, pediatrics (aged 2– 16 years) who were scheduled for selective neurosurgery were enrolled. Patients were randomized to receive combined esketamine (0.5 mg/kg) and dexmedetomidine (0.5 μg/kg) or normal saline as placebo at anesthesia induction. Primary outcome was the incidence of delirium within postoperative the first five days which was assessed twice daily using the Cornell Assessment of Pediatric Delirium (CAPD). CAPD≥ 10 at any assessment point was considered as delirium. Secondary outcomes included the incidence of emergence delirium, non-delirium complications within postoperative 30 days, postoperative length of in-hospital stay, and medical cost during hospitalization. The change of systematic inflammation was reflected by Neutrophil-to-Lymphocyte Ratio.
Results: From July 2021 to March 2023, 270 patients were screened, and 190 patients were randomized. Median age of enrolled patients was similar between two groups (63.0 [43.3, 111.3] vs 70.0 [46.3, 114.8] months, P = 0.883). Patients in esketamine-dex group suffered lower incidence of postoperative delirium than control group (intention-to-treat analysis: 22.8% [21/92] vs 38.0% [35/92], RR = 0.600, 95% CI 0.380– 0.948, P = 0.025; per-protocol analysis: 22.0% [20/91] vs 38.2% [34/89], RR = 0.575, 95% CI 0.360– 0.919, P = 0.018). The incidence of emergence delirium was lower in esketamine-dex group than control group (20.7% [19/92] vs 50.0% [46/92], RR = 0.413, 95% CI 0.263– 0.648, P < 0.001). Patients in esketamine-dex group had lower medical cost (P < 0.001), and there was no statistical significance in the incidence of non-delirium complications within postoperative 30 days and postoperative length of in-hospital stay. The neutrophil-to-lymphocyte ratios at postoperative first and third day were comparable between two groups. Safety outcomes such as bradycardia and hypotension were comparable between groups.
Conclusion: Combined esketamine and dexmedetomidine could decrease the risk postoperative delirium and emergence delirium in pediatrics after neurosurgery.
Keywords: pediatric, neurosurgery, esketamine, dexmedetomidine, delirium